Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
NCT00005612
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with autologous peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy followed by peripheral stem cell transplantation in treating patients who have ovarian epithelial cancer.
Gender:
FEMALE
Ages:
Between 18 years and 65 years
Trial Updated:
09/24/2012
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Ovarian Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer
NCT00003072
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more tumor cells. PURPOSE: Randomized phase II double-blinded trial to study the effectiveness of paclitaxel and carboplatin given with either amifostine or placebo in patients with metastatic stage III or stage IV ovarian cancer or metastatic stage III or stage IV non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2012
Locations: Oncology Service of San Francisco General Hospital Medical Center, San Francisco, California +3 locations
Conditions: Lung Cancer, Neurotoxicity, Ovarian Cancer
Register for Updates
Ph II Concurrent Chemo t/Docetaxel/Carboplatin/Radio Therapy-consolidation t/Locally Adv Inoperable Non-Small Cell Lung Cancer (NSCLC)
NCT00664105
Terminated
RATIONALE: Because of its success in advanced NSCLC both as a single agent and in combination with other chemotherapeutics, it is reasonable to investigate the efficacy and toxicity of docetaxel as a multimodality regimen in this patient population. Docetaxel at a dose of 20 mg/m2 appears to be a well-tolerated "weekly" dose when combined with either cisplatin 25 mg/m2 20-22 or carboplatin area under the curve (AUC) 2 23-25 concomitant with radiation therapy. PURPOSE: To explore the potential b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/30/2012
Locations: M.D. Anderson Cancer Center, Orlando, Orlando, Florida +14 locations
Conditions: Lung Cancer
Register for Updates
Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer
NCT00365365
Completed
This is a phase IIb, randomized, parallel-group, noncomparative, multicenter, pilot study designed to evaluate the safety and efficacy of bevacizumab with or without (+/-) trastuzumab administered with three different docetaxel-based combination regimens for the adjuvant treatment of participants with node positive or high-risk node negative breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/16/2012
Locations: Sanofi-Aventis Administrative Office, Bridgewater, New Jersey
Conditions: Breast Cancer
Register for Updates
Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2
NCT00085839
Completed
The purpose of this noncomparative study is to obtain preliminary estimates of the efficacy of erlotinib and standard chemotherapy in patients with advanced, previously untreated nonsmall cell lung cancer (NSCLC) and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2. The study will also evaluate the safety of single-agent erlotinib in this patient population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2012
Locations: California Cancer Care, Inc., Greenbrae, California +18 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
NCT00294762
Completed
This will be the first prospective study where patients will be selected on the basis of two measures of the epidermal growth factor receptor (EGFR) pathway. The study will assess prospectively the efficacy of erlotinib as a single agent or intercalated with chemotherapy in highly selected patients with EGFR overexpression and/or EGFR amplification.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2012
Locations: Central Hematology Oncology Medical Group Inc., Alhambra, California +42 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma
NCT00687687
Completed
To estimate the antitumor activity of paclitaxel, carboplatin, plus BSI-201 in patients with recurrent or advanced uterine carcinosarcomas. Based on data generated by BiPar/Sanofi, it is concluded that iniparib does not possess characteristics typical of the PARP inhibitor class. The exact mechanism has not yet been fully elucidated, however based on experiments on tumor cells performed in the laboratory, iniparib is a novel investigational anti-cancer agent that induces gamma-H2AX (a marker of... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/01/2012
Locations: Research Site, Aurora, Colorado +39 locations
Conditions: Uterine Carcinosarcoma
Register for Updates
Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer
NCT00501644
Completed
Primary Objectives: 1. Determine response rate, time to progression, and toxicity of a schedule of carboplatin by IV (intravenous) infusion, GM-CSF and rIFN-g by SC (subcutaneous injection) in patients with potentially platinum-sensitive recurrent Müllerian carcinomas. 2. Determine whether this treatment schedule is associated with: 1. increased levels of monocytes (\>2-fold and absolute numbers 1000 cells/ml,) and of LN-DR+ DC (CD11c+ and CD123+ subsets) 2. induction of priming and acti... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
08/01/2012
Locations: U.T.M.D. Anderson Cancer Center, Houston, Texas
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Register for Updates
PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer
NCT00059618
Completed
The goal of this clinical research study is to find the highest safe dose of PS-341 that can be given with carboplatin chemotherapy as a treatment for patients with ovarian, abdominal, or fallopian tube cancer. Researchers also hope to find out if giving these drugs together will help shrink or slow the growth of tumors in patients who are considered resistant to platinum drugs. The safety of these drugs will also be studied.
Gender:
FEMALE
Ages:
All
Trial Updated:
08/01/2012
Locations: University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Register for Updates
Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors
NCT00502892
Completed
Primary Objectives: * To determine the maximum tolerated dose (MTD) of Topotecan when added to a fixed dose regimen of Ifosfamide and Carboplatin in children and young adults with solid tumors. * To evaluate the toxicity associated with the administration of Topotecan with Ifosfamide and Carboplatin (TIC) in children and young adults with solid tumors. Secondary Objectives: * To evaluate the duration of neutropenia (ANC\<500/micro L) and thrombocytopenia (PLT 50,000/ micro L and 20,000/ micro... Read More
Gender:
ALL
Ages:
45 years and below
Trial Updated:
07/31/2012
Locations: U.T.M.D. Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumors
Register for Updates
Cisplatin and Pemetrexed With Radiation Followed by Lobectomy
NCT01373463
Terminated
This study is open to patients that have been diagnosed with non-squamous Stage III Non Small Cell Lung Cancer (NSCLC) and will have surgery to remove the tumor. The purpose of this study is to: * Test a combination of two chemotherapeutic drugs along with radiation therapy, when given prior to surgery and see what effects (good or bad) it has on someone with this type of cancer. Chemotherapeutic drugs selectively destroy diseased cancer cells and tissues. * Test the safety of different dose l... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/24/2012
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Nonsquamous Nonsmall Cell Neoplasm of Lung, Nonsmall Cell Lung Cancer Stage III
Register for Updates
S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT00003158
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy and chemotherapy consisting of carboplatin, etoposide and paclitaxel in treating patients with newly diagnosed stage III non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/20/2012
Locations: MBCCOP - University of South Alabama, Mobile, Alabama +85 locations
Conditions: Lung Cancer
Register for Updates